Randomized prospective study showing the non‐inferiority of tenofovir to entecavir in treatment‐naïve chronic hepatitis B patients

Publisher： John Wiley & Sons Inc

E-ISSN： 1872-034x|48|1|59-68

ISSN： 1386-6346

Source： HEPATOLOGY RESEARCH, Vol.48, Iss.1, 2018-01, pp. : 59-68

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long‐term entecavir or tenofovir disoproxil fumarate therapy in treatment‐naïve chronic hepatitis B patients in the real‐world setting

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. 5, 2015-05 ,pp. : 504-510

John Wiley & Sons Inc

Access to resources Recommend Favorite

A meta‐analysis comparing the efficacy of entecavir and tenofovir for the treatment of chronic hepatitis B infection

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 3, 2015-03 ,pp. : 288-297

John Wiley & Sons Inc

Access to resources Recommend Favorite

Tenofovir‐based alternate therapies for chronic hepatitis B patients with partial virological response to entecavir

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. 8, 2015-08 ,pp. : 675-681

John Wiley & Sons Inc

Access to resources Recommend Favorite

Tenofovir in the treatment of chronic hepatitis B

By Yu Derek   Heathcote Jenny  

Therapy, Vol. 8, Iss. 5, 2011-09 ,pp. : 527-544

Future Medicine

Access to resources Recommend Favorite

GSK2878175, a pan‐genotypic non‐nucleoside NS5B polymerase inhibitor, in healthy and treatment‐naïve chronic hepatitis C subjects

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 25, Iss. 1, 2018-01 ,pp. : 19-27

John Wiley & Sons Inc

Access to resources Recommend Favorite